ストックスクリーナーアプリを入手
6.70
2.13%
0.14
アフターアワーズ：
6.70
Entrada Therapeutics Inc (TRDA) 最新ニュース
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutics, Inc. (TRDA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Entrada Therapeutics clinical trial data sparks brutal stock selloffhere's why - MSN
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
TRDA - Finviz
Insider Move at Entrada Therapeutics Sparks Fresh Investor Interest - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Entrada Thera - The National Law Review
Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock By Investing.com - Investing.com Australia
Entrada Therapeutics director Bernhardt Zeiher buys $29,316 in stock - Investing.com
Entrada Therapeutics (TRDA) director’s trust buys 5,000 common shares - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Entrada Therapeutic - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Entrada Therapeutics, Inc. (TRDA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
User - The Chronicle-Journal
Entrada Therapeutics Reports Positive Phase 1/2 Results for ENTR-601-44 in Duchenne Muscular Dystrophy, Highlighting Best-in-Class Potential and $5B U.S. Market Opportunity 679 - Minichart
Entrada Therapeutics Highlights Transformational Year and Pipeline Progress - TipRanks
Entrada Therapeutics updates corporate presentation, cites DMD Cohort 1 safety and functional gains; Cohort 2/45 data due 2026 - TradingView
Entrada Therapeutics (TRDA) furnishes updated corporate presentation to investors - Stock Titan
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewir - The National Law Review
INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC - GlobeNewswire
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Scott Coop
Entrada Therapeutics, Inc. (TRDA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
(TRDA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Entrada Therapeutics faces investigation after drug trial results disappoint, stock plunges 57%. - Pluang
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc.TRDA - PR Newswire
Entrada Therapeutics, Inc. Common Stock (TRDA) Stock Price Today & Analysis - Gotrade
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
HC Wainwright Has Positive Estimate for TRDA Q2 Earnings - MarketBeat
TradingKey - TradingKey
Investors in Entrada Therapeutics urged to join probe after stock drops on clinical trial results - Pluang
Entrada Therapeutics, Inc. Shareholders Are Encouraged to - GlobeNewswire
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $10 - Moomoo
MSN Money - MSN
Transcript : Entrada Therapeutics, Inc., Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile - Barchart.com
Entrada Therapeutics, Inc.Common Stock (NQ: TRDA - FinancialContent
Roth MKM Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Cuts Target Price to $10 - Moomoo
Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock SelloffHere's Why - Sahm
Entrada Therapeutics Cut to Neutral From Buy by HC Wainwright & Co. - Moomoo
This HubSpot Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - Benzinga
H.C. Wainwright Downgrades Entrada Therapeutics(TRDA.US) to Hold Rating - Moomoo
Entrada’s stock drops as DMD drug’s efficacy falls short - Yahoo Finance
Entrada Therapeutics Declines on Duchenne Muscular Dystrophy Study Data -- Update - Moomoo
Entrada’s ENTR-601-44 Shows Efficacy, But Dystrophin Raises Questions - Citeline News & Insights
Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Entrada sinks on mixed DMD data with ENTR-601-44 - BioWorld News
Entrada Therapeutics Announces Positive Topline Results from Coho - The National Law Review
Entrada plunges on trial data for Duchenne drug (TRDA:NASDAQ) - Seeking Alpha
Entrada shares sink after Duchenne drug falls short of expectations - WHTC
Entrada Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study - markets.businessinsider.com
Entrada Therapeutics (NASDAQ:TRDA) Plunges Nearly 48% as Early-Stage DMD Clinical Data Disappoints on Drug Exposure - ChartMill
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Entrada posts strong ENTR-601-44 Duchenne Phase 1/2 data - TipRanks
Entrada Therapeutics : Corporate Presentation May 2026 - marketscreener.com
Entrada Therapeutics Reports First Quarter 2026 Financial Results - The Manila Times
Entrada Therapeutics Reports Positive Topline Results from ELEVATE-44-201 Study in Duchenne Muscular Dystrophy and Updates on Clinical Pipeline and Financial Position - Quiver Quantitative
Entrada Therapeutics: On Track to Report ELEVATE-45-201 Cohort 1 Data in Mid-2026 >TRDA - Moomoo
Entrada Therapeutics (NASDAQ: TRDA) widens loss but reports cash runway into 2027 - Stock Titan
Entrada shares dive as Duchenne results disappoint - Yahoo Finance
Entrada posts early Duchenne benefit, says cash lasts into Q3 2027 - Stock Titan
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):